5 analysts have expressed a variety of opinions on Arvinas ARVN over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 2 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $71.4, a high estimate of $88.00, and a low estimate of $40.00. Highlighting a 9.04% decrease, the current average has fallen from the previous average price target of $78.50.
Breaking Down Analyst Ratings: A Detailed Examination
In examining recent analyst actions, we gain insights into how financial experts perceive Arvinas. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $87.00 | $87.00 |
| Etzer Darout | BMO Capital | Lowers | Outperform | $88.00 | $90.00 |
| Sudan Loganathan | Stephens & Co. | Announces | Overweight | $55.00 | - |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $87.00 | $87.00 |
| Matthew Biegler | Oppenheimer | Lowers | Outperform | $40.00 | $50.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Arvinas. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Arvinas compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Arvinas's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Arvinas's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Arvinas analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About Arvinas
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Understanding the Numbers: Arvinas's Finances
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Arvinas displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 195.95%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Arvinas's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -48.05%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Arvinas's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -8.3%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Arvinas's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -4.02%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Arvinas's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Significance of Analyst Ratings Explained
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
